Key Takeaways
- Boehringer Ingelheim launches VETMEDIN® Solution, the first FDA-approved oral liquid for congestive heart failure in dogs.
- This innovative solution addresses heart disease in dogs, which affects 10% of the canine population.
- VETMEDIN® Solution improves survival time and quality of life for dogs with CHF caused by MMVD or DCM.
Boehringer Ingelheim, a leader in animal health, has launched VETMEDIN® Solution, the first FDA-approved oral liquid for managing congestive heart failure (CHF) in dogs. CHF is a significant health issue in dogs, with approximately 10% experiencing heart disease in their lifetime. The most common causes include myxomatous mitral valve disease (MMVD) and dilated cardiomyopathy (DCM), both of which can progress to CHF.
VETMEDIN® Solution offers a new, convenient alternative for pet owners, particularly for dogs that struggle with chewable tablets. With a flavorless liquid formulation, it provides the same dual-action benefits as the chewable version, helping to increase survival time and enhance the quality of life for dogs with CHF due to MMVD or DCM. This innovation reflects Boehringer Ingelheim’s commitment to advancing veterinary care and addressing unmet needs in the field of animal health.
Proven Benefits and Broad Applications
VETMEDIN® has been a cornerstone of canine cardiology since its introduction 25 years ago, contributing over one million additional years of life for dogs worldwide. Previous studies have demonstrated its efficacy in managing CHF by improving heart function and reducing symptoms. The liquid version builds on this legacy, offering a versatile solution for dogs of all sizes, especially smaller breeds that may prefer liquid medication.
The introduction of VETMEDIN® Solution comes at a time when heart disease in dogs is increasingly recognized as a critical health challenge. Daniel Watkins, VP of the U.S. Pet Business at Boehringer Ingelheim, stated, “We know some dogs and pet owners prefer a liquid medication. With VETMEDIN® Solution, we can help more dogs with heart disease have longer survival and live better lives.”
Additionally, Boehringer Ingelheim provides VETMEDIN®-CA1 (pimobendan), conditionally approved by the FDA for dogs with preclinical MMVD (Stage B2), which aims to delay the onset of heart failure symptoms. Together, these products offer comprehensive solutions for managing canine heart disease at various stages.
Addressing a Critical Health Need
Heart disease in dogs mirrors its prevalence in humans, underscoring the need for advanced treatment options. MMVD and DCM are progressive conditions that lead to CHF, characterized by the heart’s inability to pump blood effectively. Symptoms include fatigue, difficulty breathing, and reduced activity levels, significantly impacting a dog’s quality of life.
VETMEDIN® Solution, administered twice daily directly into a dog’s mouth, simplifies the treatment process for pet owners. Its FDA approval reinforces its safety and efficacy, and its introduction into the U.S. market marks a major milestone in veterinary medicine.
Boehringer Ingelheim’s continued investment in research and development is evident in the rigorous studies supporting VETMEDIN®. The company has consistently demonstrated its leadership in addressing high unmet medical needs for both human and animal health, ensuring that veterinary solutions keep pace with evolving challenges.
Boehringer Ingelheim’s Commitment to Animal Health
As a global leader in animal health, Boehringer Ingelheim is dedicated to improving the lives of pets and their owners through innovative therapies. With a wide portfolio of vaccines, parasite-control products, and medicines, the company serves veterinarians, pet owners, and livestock producers across over 130 markets.
The launch of VETMEDIN® Solution highlights Boehringer Ingelheim’s focus on providing practical, evidence-based solutions to enhance the well-being of animals. By prioritizing the health of pets and recognizing the deep connection between human and animal health, the company continues to drive meaningful change in veterinary medicine.
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
